Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jack Eff"'
Publikováno v:
The American Journal of Cardiology. 80:421-425
Myocardial ischemia occurs frequently during daily life and has a circadian pattern similar to that reported for myocardial infarction and sudden death. Because of the increased risk of myocardial ischemia in the morning hours, it has been suggested
Publikováno v:
Clinical Cardiology. 17:484-488
This multicenter, open-label, single crossover study examined 195 patients taking an immediate-release diltiazem tablet as chronic stable angina therapy to determine if apparently logical methods of converting them to an extended-release, once-daily
Autor:
Donald B. Hunninghake, S. Jolene Held, Jack Eff, Antonio M. Gotto, W.Dallas Hall, Lawrence Ferraro, Mario I. Sztern, Brian F. Johnson, Alan Herd, Carlos A. Dujovne, William S. Harris, Robert J. Goldstein
Publikováno v:
The American Journal of Cardiology. 72:1131-1136
Antihypertensive drugs may affect serum lipoprotein levels in mixed populations but data in hyperlipidemic patients are scanty. Atenolol versus celiprolol effects on serum lipoproteins were compared in 159 hyperlipoproteinemic hypertensive patients.
Publikováno v:
The Journal of Clinical Pharmacology. 32:808-815
A new polymeric matrix technology provides a sustained-release formulation of diltiazem hydrochloride (diltiazem SR) suitable for once-daily therapy. The efficacy and safety of diltiazem SR were evaluated in a multicenter, randomized, double-blind, p
Publikováno v:
The American Journal of Cardiology. 67:665-670
The comparative antianginal effects and safety of propranolol and celiprolol, a highly beta 1-selective adrenoceptor blocker with selective partial beta 2-adrenoceptor agonist activity, were assessed in an international multicenter, placebo run-in, a
Autor:
Steven G. Chrysant, Stephen L. Archer, Eric P. Brass, Jack Eff, Robert Fiddes, Gregg Fromell, Neal R. Cutler
Publikováno v:
Journal of clinical pharmacology. 35(2)
A double-blind safety and efficacy dose-ranging study was conducted with a new, once-daily, extended-release (XR) diltiazem hydrochloride formulation (Dilacor XR, Rhone-Poulenc Rorer, Collegeville, PA) in 189 patients with chronic stable angina pecto
Publikováno v:
Journal of Cardiovascular Pharmacology. 8:S132-S134
This double-blind, placebo-controlled, parallel, multicenter study was designed to evaluate the anti-anginal and anti-ischemic effects of celiprolol in patients with stable, exercise-induced angina pectoris. The study began with a 4-week single-blind